Discover
TOVX
Theriva Biologics, Inc.
0.23
1 x 0.21
1 x 0.25
bid
ask
+
0.00
0.22%
09:30 AM
timesize
| Ytd | 9.55% | |
| 1y | -53.33% |
0.23
day range
0.23
0.16
52 week range
0.86
| Open | 0.23 | Prev Close | 0.23 | Low | 0.23 | High | 0.23 | Mkt Cap | 8.21M |
| Vol | 98.32K | Avg Vol | 7.62M | EPS | -0.58 | P/E | -0.40 | Forward P/E | -0.07 |
| Beta | 1.09 | Short Ratio | 0.03 | Inst. Own | 21.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.27 | 200-d Avg | 0.26 | 1yr Est | 90.50 |
| Income Statement | |||
| Total Revenue | 300.00K | ||
| Revenues (USD) | 300.00K | ||
| Gross Profit | 300.00K | ||
| Operating Expenses | 2.43M | ||
| Research and Development Expense | 355.00K | ||
| Selling, General and Administrative Expense | 2.07M | ||
| Operating Income | -2.13M | ||
| Net Income | -2.04M | ||
| Net Income Common Stock | -2.04M | ||
| Net Income Common Stock (USD) | -2.04M | ||
| Consolidated Income | -2.04M | ||
| Earnings per Basic Share | -0.05 | ||
| Earnings per Basic Share (USD) | -0.05 | ||
| Earnings per Diluted Share | -0.05 | ||
| Earning Before Interest & Taxes (EBIT) | -2.04M | ||
| Earning Before Interest & Taxes (USD) | -2.04M | ||
| Weighted Average Shares | 41.07M | ||
| Weighted Average Shares Diluted | 41.07M | ||
| Balance Sheet | |||
| Cash and Equivalents | 14.48M | ||
| Cash and Equivalents (USD) | 14.48M | ||
| Current Assets | 16.76M | ||
| Property, Plant & Equipment Net | 2.14M | ||
| Total Assets | 38.25M | ||
| Debt Current | 545.00K | ||
| Total Debt | 3.69M | ||
| Current Liabilities | 10.26M | ||
| Debt Non-Current | 3.15M | ||
| Total Liabilities | 22.85M | ||
| Accumulated Retained Earnings (Deficit) | -360.75M | ||
| Accumulated Other Comprehensive Income | 377.00K | ||
| Shareholders Equity | 15.40M | ||
| Shareholders Equity (USD) | 15.40M | ||
| Assets Non-Current | 21.49M | ||
| Total Debt (USD) | 3.69M | ||
| Liabilities Non-Current | 12.59M | ||
| Trade and Non-Trade Payables | 608.00K | ||
| Tax Assets | 1.70M | ||
| Tax Liabilities | 2.03M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 167.00K | ||
| Net Cash Flow from Financing | 3.87M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 1.37M | ||
| Issuance (Purchase) of Equity Shares | 2.30M | ||
| Issuance (Repayment) of Debt Securities | -49.00K | ||
| Net Cash Flow from Operations | -2.46M | ||
| Effect of Exchange Rate Changes on Cash | -36.00K | ||
| Share Based Compensation | 135.00K | ||